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INTRODUCTION
Urothelial carcinoma of the urinary bladder is the fifth most common cancer in the Western world, and the ninth most frequent cancer worldwide, representing 3% of cancers diagnosed globally (1) . Treatment of bladder cancer has not changed significantly in over 20 years, and outcomes for patients remain suboptimal. Approximately 20-30% of newly diagnosed patients present with muscle-invasive (MI) disease (stages T2-4) or metastatic disease, while up to a third of patients with initially non-muscle-invasive (non-MI) disease (stages Ta/T1/Tis) later progress to MI or metastatic disease (2) . Clinical features including stage and grade are strongly associated with outcome and play an important role in determining treatment. For example, the 5-year tumor-specific mortality rates range from less than 5% for low-stage and low-grade disease up to approximately 50% for all MI lesions (3, 4) . However, even though grade and stage are important predictors of outcome, there remains significant variability in the prognosis of patients with similar characteristics. This highlights the need to identify additional tumor characteristics that predict clinical behavior.
In recent years, there has been a growing interest in the use of gene expression signatures for risk stratification of cancer patients (5) . Multiple groups have produced urothelial cancer gene signatures predictive of a range of tumor characteristics and outcomes, including stage (6-8), molecular subtype (9, 10) , likelihood of recurrence and progression of non-MI (11) (12) (13) and MI disease (14), and survival (7). Here we aimed to (i) explore if novel cancer gene expression patterns can be identified that stratify patients undergoing radical cystectomy for urothelial cancer by risk of recurrence and death; (ii) test our novel signatures and all previously developed signatures in all available bladder cancer microarray datasets; and (iii) investigate the gain in predictive accuracy of a validated clinical nomogram by combination with gene signature information.
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MATERIALS AND METHODS

MSKCC Samples
Characteristics. We utilized previously unpublished cancer gene expression data from 93 patients undergoing radical cystectomy (RC) at Memorial Sloan-Kettering Cancer Center (MSKCC) between 1993 and 2004. Specimens were collected with MSKCC Institutional Review Board approval, and a waiver of authorization to review associated clinical data was obtained from the Board. The clinicopathologic characteristics are summarized in Table 1 (see Table S1 for details). In those 15 patients with non-MI disease on final pathologic analysis after RC, four had MI disease histologically in tissue obtained at the time of prior transurethral resection (TUR), and the remaining patients had high-risk features (e.g. extensive volume of disease, recurrent or BCG-refractory disease). Lymph node dissection was performed in 77 patients; no patient had metastatic disease at the time of RC. Chemotherapy was administered to 3 patients as neoadjuvant, 16 patients as adjuvant, and 19 patients as salvage for recurrent disease. Case selection was restricted to those with frozen specimens with measurable volume of malignancy and adequate percentage of tumor.
Clinical endpoints. Overall survival time was defined as the time from date of RC to date of death or last follow-up. Disease-specific survival was defined as the time from RC to death attributed to urothelial cancer, when death occurred with known and progressive metastatic disease. If death was recorded in the institutional database without knowledge of a recurrent cancer or with documentation of another malignancy or a non-malignancy cause, death was attributed to other causes. Recurrence was defined as pelvic if within the pelvis below the aortic bifurcation, distant if there was visceral metastasis or recurrence above the aortic bifurcation, and urothelial if within the remaining urinary tract (renal pelvis, ureter, urethra).
In the analysis of the development of metastases, only pelvic and distance recurrences were included. Primary endpoint in this study was overall survival if not mentioned otherwise. content by pathologic review. RNA was isolated with Trizol (Invitrogen) and cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols. Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit).
Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics). Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays, containing 54,675 probe sets. Data was uploaded to NCBI Geo (15) under accession number GSE31684.
External datasets
We obtained six independent bladder cancer microarray datasets (6, 7, 9, 10, 13, 16) ( Table 2) totaling 578 additional patients and encompassing a broad spectrum of stages, grades, and histologic types. 
Statistical analysis
Preprocessing. Expression estimates were obtained by the GCRMA algorithm (17) .
Differential gene expression. The gene expression profiles were evaluated for significant correlation with multiple clinical variables and outcomes, including stage, lymph node status, recurrence, and overall survival. For the identification of differentially expressed probe sets, we used the LIMMA method (18) . If not stated otherwise, the cutoff of the adjusted p-values (the false discovery rate, FDR) (19) was set to 0.01 and the minimum fold change (FC) to 1.5.
The probability of observing n or more differentially expressed genes was estimated by permutation tests. For the external datasets, the lists of differentially expressed genes were downloaded from the supplementary material of the respective papers (6, 7, 9, 10, 13, 16) expressed genes with corresponding lists from external datasets, the significance of overlaps was calculated in Bioconductor (GSEABase), using 25,000 permutations.
Machine learning. Classifiers were generated with Fisher's linear discriminant and support vector machines (SVMs) and were leave-one-out cross-validated. The R packages MASS and e1071 were used for building the classifiers. We utilized a linear SVM kernel and default, untuned parameters. ROC curves were generated with the ROCR package (20) .
Risk category creation. For each patient, a risk score was calculated by a Cox proportional hazards model that was fitted using the gene expression profiles of all remaining patient samples (leave-one-out cross-validation). The risk score was defined as the sum of the gene signature expression values, weighted by the Cox regression coefficients (21) . Each individual was then classified into low-risk or high-risk categories, based on the median leave-one-out cross-validated risk score: patients were classified as low-risk when their risk score was smaller than the cohort median, otherwise as high-risk. This was done independently for all datasets for which survival information was available. The significance of survival curve differences of cross-validated models was estimated with permutation tests. The process from crossvalidation to risk stratification was repeated 500 times with shuffled survival labels. This empirical chi-square distribution was then utilized to estimate p-values. For non-crossvalidated models, the log-rank test was used. Multivariate survival prediction models were compared by the C-statistic, an estimator of the model concordance (22) , and by likelihoodratio tests. The concordance represents the probability that given two random non-censored individuals, the one with the higher risk score has a shorter survival time.
Clustering analysis. For unsupervised clustering, we used the Ward clustering method and the Pearson correlation distance as implemented in the pvclust R package (23) . The significance of a cluster was reported as its bootstrap value, which is the proportion of 10,000 bootstrap samples showing this particular cluster topology. The clustering was applied to the six external datasets of bladder cancer samples.
Research. (11) (12) (13) (14) and melanoma signatures (25, 26) ; the melanoma signatures were included to test whether signatures from other solid tumors would perform well in bladder cancer. The 49 gene signatures were tested in our dataset and the 4 external gene expression datasets with survival information.
Associations of gene expression signatures with outcome and other covariates were calculated using globaltest (27) ; this test can be used to estimate whether the expression of a group of genes is significantly associated with a particular response variable, for example stage or survival. Gene signatures were further tested by leave-one-out cross-validation. To avoid problems with highly correlated covariates in multivariate Cox proportional hazards models, expression values were scaled by principal component analysis (PCA). The number of components was chosen so that at least 99% of the expression variance was included in the model, with a maximum of 20 components. The choice of this cutoff was examined by varying the maximum number of components from 3 to 30 (Table S2 ). The performance of these cross-validated models was reported as the C-statistic of a univariate Cox model with the risk score as covariate.
Feature selection. The signatures were optimized by stepwise selection, an iterative procedure which serially removes and adds probe sets from a pool of candidates. The procedure was terminated when adding, removing or replacing a probe set did not further significantly improve the mean leave-one-out cross-validated Area Under Receiver Operating Curve (AUC) (for the stage and subtype signatures) or C-statistic (for the survival signature) over all datasets (see Supplemental Data for details). Thus all datasets were used for training and validation. In total, over a million promising signatures were cross-validated in all datasets.
Addition of new survival signature to existing predictive model for recurrence-free survival
We calculated the recurrence-free survival probabilities in our patients using the postoperative nomogram developed by the International Bladder Cancer Nomogram Consortium (IBCNC) (28) . This nomogram, developed from data of over 9,000 patients, includes age, sex, time from In Figure 1 , we provide an overview of the analyses performed in this study. 
RESULTS
Differentially expressed genes are associated with clinical features and outcome
Comparison by pathologic stage. When comparing non-MI with MI samples in our data set, we found 636 significantly differentially expressed probe sets, which significantly overlapped with the corresponding lists of genes in the six independent studies (P < 0.0001, Tables S3a, S4- (Table S6) identified MI tumors with a mean accuracy of 89.0% (88.4% SVM, Figure S2 ) over all datasets.
Comparison by recurrence status. We then compared the gene expression patterns of patients who developed metastasis (pelvic or distant recurrence) and died of bladder cancer with those of patients who did not. When considering samples of all stages, we identified no significantly differentially expressed genes. However, when restricting this comparison to patients with pathologically organ-confined MI (pT2N0) tumors (17 patients, 5 of whom developed metastasis), we identified 53 differentially expressed genes with FDR < 10% in our dataset (P < 0.06, Table S3b ). In the external datasets, the number of pT2N0 tumors with later metastasis was too small for the identification of significantly differentially expressed genes in this comparison. Among those genes that were differentially expressed in patients who developed metastasis and died were PERP (a TP53 apoptosis factor), ATXN10 (an activator of the Ras-MAPK pathway) [24] ; and PCM1 (associated with papillary thyroid cancer, chronic myeloid leukemia, and myeloproliferative disorders) [25] .
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Identification of a robust survival signature for MI tumors
Validation of published signatures. We then evaluated 49 published gene signatures (Table S2) alongside our classifiers described above for correlation with clinical features in our dataset and with the four independent gene expression datasets with available survival information (6, 7, 9, 13) . Due to the smaller number of genes on the Lindgren et al. and Blaveri et al. cDNA microarrays, only fractions of these signatures' genes could be mapped. We observed overfitting of published survival signatures so that most signatures achieved significance, in terms of survival information, only in the datasets used to identify them ( Table 3) Table S2) . Especially striking are MAP kinases, with different members present in various signatures (7, 9, 11, 14, 29) .
Validation of published signatures, stratified by molecular subtype. As reported in multiple other studies (6, 7, 9) , bladder tumors cluster in two very distinct molecular subtypes. We reproduced this finding in all analyzed datasets ( Figure S4 ) and further, found significant differences in survival between the two subtypes ( Figure S5) . The expression differences between the subtypes were remarkable and overlapped significantly across datasets (P < 0.00004, Table S5 ). This allowed a robust classification of tumors by subtype with a novel 19-gene signature (Table S7, Figure S6 ). The very heterogeneous landscape of MI bladder tumors motivated us to evaluate the performance of all signatures in the two subtypes separately.
Two progression signatures, one developed for bladder (6) and one for breast cancer (30), were significantly associated with survival in our cohort when applied to one of the two subtypes ( Figure S7) . By analyzing primary and recurrent tumors from the Kim et al. cohort (13) , we found evidence that tumors can progress from one molecular subtype to the other (Table S8 ).
Curation of a novel survival signature. We then curated a new 20-gene overall survival signature for MI tumors (Table 4 ) by stepwise optimization and tested its predictive accuracy in our dataset and the four external datasets with available survival information. A leave-oneout cross-validated multivariate Cox proportional hazards model based on this signature classified tumors into two equally sized risk groups with significantly different survival in all datasets (Figure 2a-e) . As an example, with the model applied to the dataset by Kim et al. (13) , there was a 5-fold increase in the risk of death in those classified as high-risk (HR 5.05, 95% CI 2.26 -11.3, P < 0.008) compared to those classified as low-risk. See Figures S8-S9 for details of the signature. Neoadjuvant chemotherapy, administered to three patients in our cohort, had no impact on the prediction accuracies (Table S9) . We next compared the prediction accuracies of the signature with pathologic stage and grade in all cohorts and found highly significant improvements of model concordance and likelihood in all datasets (mean ΔC-statistic: 0.14, 95% CI 0.01-0.27; likelihood-ratio test: P < 0.001; Figure 2f , Table S10 ).
Addition of survival signature to the nomogram increases its predictive accuracy
We then incorporated the new signature developed for MI tumors (Table 4) 
DISCUSSION
This study demonstrates the utility of adding molecular information to an existing prognostic tool in bladder cancer patients who undergo RC. Gene expression data from a new cohort of bladder cancer patients was analyzed and compared to gene expression data from multiple published studies. A robust expression signature was identified that improved the predictive outcome of a well-accepted nomogram, and was independently predictive of survival in all cohorts where survival data was available. These findings are particularly striking given the relative homogeneity of the population analyzed, since our cohort, having all undergone the most aggressive surgical therapy, is highly selected for being at high risk of death from disease.
One important contribution of this study is the clinical validation of published gene signatures.
To be clinically relevant, new survival markers must (i) stratify patients in groups with significantly different survival; (ii) deliver survival information that is not already included in established clinically used predictors such as grade and stage; and (iii) increase the accuracies of existing prediction models to an extent that warrants the cost and effort of obtaining biomarker status (31) . Previously published gene signatures (Table S2) , however, performed poorly in our patient cohort: no gene signature provided more survival information than would be expected by chance. This finding can partly be explained by cross-platform issues like incomplete mapping of genes to available probe sets or probe sets targeting different exons.
Another reason is a likely overfitting of published signatures due to rather small training datasets for the very heterogeneous group of MI bladder cancers. To circumvent these limitations, we optimized the survival signatures for the subgroup of MI tumors, and showed that gene expression clearly stratifies patients into 2 groups, denoted as low-risk and high-risk.
The new signature further segregated by risk 305 patients with MI tumors in the external datasets containing gene expression and survival information. Interestingly, 4 genes in our MI survival signature, APOBEC3B, DGCR2, PRMT1, SLC1A5, are located on chromosomes 22 and 19, in neighboring chromosome bands of SNPs recently described as associated with an increased risk of developing bladder cancer (32) . In addition to our signature, several other genes (Table S2 ) significantly correlated with survival in multiple independent cohorts. These of similar cystectomy samples is essential. An interesting additional opportunity for evaluation would be among patients with MI disease at the time of TUR-by characterizing a greater risk of aggressive behavior, we may more carefully select patients for chemotherapy prior to radical surgery as well, to improve our survival outcomes using multimodal therapy.
We found that fibronectin 1 (FN1) was significantly overexpressed in MI tumors as compared to non-MI samples in all datasets we analyzed. The role of FN1 in cancer invasion and metastasis is still poorly understood, but its increased expression might be the result of an enhanced recruitment of cancer-associated fibroblasts (33, 34) . The consistency across datasets suggests that the abundant differential expression of FN1 and other extracellular matrix (ECM) genes is unlikely due to stromal contamination. Our stage classifier (Table S6) could identify patients as having MI disease with a mean accuracy of 89%, which is within the range of previously published classifiers (6, 24) . However, our stage classifier was validated in more datasets and consists of fewer genes than the published classifiers, which offer advantages for its potential clinical use. Furthermore, the accuracy rate of 89% does not imply a false classification rate of 11% as some tumors might have been incorrectly classified histologically. Urothelial cancer of the bladder is exceptionally difficult to stage accurately prior to cystectomy, given technical limitations of endoscopic resection and imaging. Significant rates of upstaging from time of TUR to RC have been reported, ranging from 31-61% (35-37).
In our patient cohort, over 80% of the tumors were determined to have higher pathologic stage at the time of cystectomy, when compared to the preoperative TUR specimens, with many tumors found to be locally advanced (>pT2) when clinically staged as organ-confined (<pT2).
The unsupervised clustering produced two strikingly different groups of patients, who were not clearly distinguishable by many clinical variables such as the presence of lymph node metastases or recurrence status. Gene expression showed large differences between the two groups (Table S3c) with highly significant overlaps in all datasets (Table S5) , allowing a robust identification of cluster membership by a 19-gene signature (Table S7) validation steps, although this concern is mitigated through the use of statistical methods such as cross-validation. This points to the imperative for validation in independent data of any gene signature associated with survival. Such a validation is necessary because signatures established from single, moderately sized datasets often perform poorly in external data due to the relatively high probability that genes correlate with survival by chance. However, extending the sample size with independent data, as performed here, can minimize this problem. For example, a gene found to be predictive in one dataset could arise due to chance, but if one gene is predictive with consistent expression in multiple datasets, it is more likely to be a robust survival marker.
A considerable strength of our investigation is its comprehensive effort to combine the majority of published data on gene expression in bladder cancer, all arrayed on different platforms, in a meaningful way. With this study, we have shown that meta-analyses across platforms are feasible. Especially in rare cancers or subtypes, the increase in sample size might often outweigh the disadvantages of meta-analyses, such as the heterogeneity of patient cohorts, the different treatments before and after surgery, and the decrease in potential markers when focusing on genes present on all platforms. Nonetheless, large independent patients cohorts are needed for further validation and optimization (i.e., for other endpoints such as recurrence-free survival or for particular microarray platforms) of the prognostic signatures, before warranting a clinical trial (38) . The results of this study strongly motivate such sample collection for urothelial tumors. investigation. The identification of patients at higher risk for progression or death will provide additional rationale for multimodality management, using chemotherapy and surgery, in an effort to improve survival. Figure 1 . Overview of the study. This study represents a massive meta-analysis of our cohort of high-risk bladder cancer patients ( Table 1 ) and 6 independent studies ( Table 2 (27) . The C-statistic (C) of a leave-one-out cross-validated Cox model with the gene intensities as covariates is reported as a second performance measure. A C of 0.5 corresponds to a random model, one of 1.0 to a perfect model. All signatures were originally identified with the corresponding dataset, except for the Smith et al. signature (14), which was obtained by training with the Sanchez-Carbayo dataset (7) and with unpublished data. Our signature was obtained by using all datasets for training. Tested right endpoint was overall survival in all datasets, not necessarily the endpoint for which the signature was designed for. See Figure S6 for a detailed analysis of 41 other signatures. 
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